Evidence-Based Summary
These drugs are not alternatives to each other. Setmelanotide (Imcivree) activates the MC4 receptor and is approved only for obesity caused by Bardet-Biedl syndrome, by POMC, PCSK1 or LEPR deficiency confirmed by genetic testing, or by acquired hypothalamic damage. Its label states it is not indicated for, and would not be expected to work in, general (polygenic) obesity. Semaglutide (Wegovy) activates the GLP-1 receptor and is approved for common obesity, and for overweight with a weight-related condition, as well as cardiovascular risk reduction. No trial has compared them, and their evidence comes from very different populations: setmelanotide from small rare-disease trials (21 to 120 people), semaglutide from trials of thousands.
Quick Comparison: Setmelanotide vs Semaglutide
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Setmelanotide | Semaglutide |
|---|---|---|
| Drug class | Melanocortin-4 (MC4) receptor agonist; small cyclic peptide | GLP-1 receptor agonist; acylated peptide |
| Target receptor | MC4 receptor in the brain's appetite pathway (with weaker MC1 activity that darkens skin) | GLP-1 receptor |
| Who it is for | Rare obesity: Bardet-Biedl syndrome; genetically confirmed POMC, PCSK1 or LEPR deficiency (age 2+); acquired hypothalamic obesity (age 4+) | Common obesity (adults and children 12+); adults with overweight and a weight-related condition |
| How it is given | Once-daily injection under the skin | Once-weekly injection or once-daily tablet (Wegovy) |
| U.S. regulatory status | FDA-approved (Imcivree); label excludes general obesity | FDA-approved (Wegovy) for weight management and cardiovascular risk reduction; other semaglutide products for diabetes |
| Strongest human evidence | Small single-arm and randomized rare-disease trials; one 120-person randomized trial in hypothalamic obesity | Large randomized trials (STEP 1: 1,961 people; SELECT: 17,604) |
| Main safety concerns | Skin darkening and new or darker moles, sexual-arousal effects, depression and suicidal thoughts, hypersensitivity | Gastrointestinal effects; thyroid C-cell tumor boxed warning (rodent data); pancreatitis, gallbladder disease |
| Direct comparison trial | None | None |
| WADA status (2026) | Not named on the Prohibited List | Not named on the Prohibited List |
Two Different Appetite Pathways
Setmelanotide stands in for a missing signal inside a specific brain pathway (the leptin-melanocortin pathway). When that pathway is broken by certain gene variants or hypothalamic injury, the MC4 receptor stops receiving its normal signal. Semaglutide acts on a different hormone receptor that is present and working in most people with obesity.
Setmelanotide
Primary Target: Melanocortin-4 (MC4) receptor
Affinity Profile: MC4 agonist; much weaker at MC1 and MC3 receptors
Activates the MC4 receptor downstream of POMC and leptin-receptor signalling, restoring a satiety signal that the rare disorders disrupt. Residual MC1 activity on pigment cells explains skin darkening.
Semaglutide
Primary Targets: GLP-1 receptor
Affinity Profile: Selective GLP-1 receptor agonist
Activates GLP-1 receptors involved in appetite, insulin release and stomach emptying. It does not depend on a working melanocortin pathway, and it has not been tested against setmelanotide in rare obesity disorders.
Approved for Different Populations
Checked 11 October 2026 against Drugs@FDA and DailyMed. Each label defines who the medicine is for; neither label covers the other's population.
Setmelanotide Status & Formulations
Imcivree (NDA 213793, Rhythm Pharmaceuticals) is approved to reduce excess body weight and maintain weight reduction long term in patients aged 2 and older with Bardet-Biedl syndrome or with POMC, PCSK1 or LEPR deficiency confirmed by genetic testing, and in patients aged 4 and older with acquired hypothalamic obesity (added in 2026).
Semaglutide Status & Formulations
Wegovy injection is approved, with diet and activity, to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce and maintain body weight in adults and children aged 12 and older with obesity and in adults with overweight and a weight-related condition; and, under accelerated approval, for noncirrhotic MASH with moderate-to-advanced fibrosis in adults. Wegovy tablets have their own indications. Ozempic and Rybelsus are diabetes products.
Critical Regulatory Distinction
The Imcivree label states it is not indicated for obesity related to benign or likely benign POMC, PCSK1 or LEPR variants, other genetic syndromes or general (polygenic) obesity, because it would not be expected to work. Using it as a general weight-loss drug is outside its approval.
Rare-Disease Trials vs Large Population Trials
The setmelanotide trials enrolled people with specific diagnoses, often children, and used endpoints such as the share losing at least 10% of body weight. The semaglutide trials enrolled thousands of adults with common obesity. The numbers cannot be compared directly.
Setmelanotide: Clinical Evidence Overview
In two single-arm Phase 3 trials, 8 of 10 people (80%) with POMC deficiency and 5 of 11 (45%) with LEPR deficiency lost at least 10% of body weight at about one year. In Bardet-Biedl syndrome, 32.3% of patients aged 12 and older reached a 10% reduction after 52 weeks, following only a 14-week placebo-controlled period. In acquired hypothalamic obesity, a randomized trial of 120 participants found BMI changed by −16.5% with setmelanotide versus +3.3% with placebo at 52 weeks.
Semaglutide: Clinical Evidence Overview
STEP 1 randomized 1,961 adults with obesity or overweight without diabetes: mean weight change was −14.9% with semaglutide versus −2.4% with placebo over 68 weeks. SELECT randomized 17,604 adults with cardiovascular disease and overweight or obesity: major cardiovascular events occurred in 6.5% versus 8.0% (HR 0.80, 95% CI 0.72–0.90). These trials did not focus on people with the rare disorders that setmelanotide treats.
Curated Clinical Evidence Table
A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.
| Study & Citation | Population | Comparison & Dosing | Duration | Main Endpoint | Key Finding | Methodological Limitations |
|---|---|---|---|---|---|---|
| POMC and LEPR trials (Clément et al., Lancet Diabetes Endocrinol 2020) | 21 people aged 6+ with POMC or LEPR deficiency | Setmelanotide, single-arm with brief blinded withdrawal | About 1 year | Share losing ≥10% of body weight | 80% (POMC) and 45% (LEPR). | Very small; no parallel control group. |
| Bardet-Biedl and Alström (Haqq et al., Lancet Diabetes Endocrinol 2022) | 38 patients aged 6+ | Setmelanotide vs placebo for 14 weeks, then open-label | 66 weeks total | Share aged 12+ with BBS losing ≥10% at 52 weeks | 32.3% (95% CI 16.7–51.4). | Main endpoint from the open-label period; Alström results inconclusive. |
| Acquired hypothalamic obesity (Miller et al., NEJM 2026) | 120 people aged 4–66 | Setmelanotide vs placebo (2:1) | 52 weeks | Percentage change in BMI | −16.5% vs +3.3%. | More serious adverse events with setmelanotide; sponsor-funded. |
| STEP 1 (Wilding et al., NEJM 2021) | 1,961 adults with obesity or overweight, no diabetes | Semaglutide vs placebo | 68 weeks | Percentage change in body weight | −14.9% vs −2.4%. | Common obesity; not people with rare melanocortin-pathway disorders. |
| SELECT (Lincoff et al., NEJM 2023) | 17,604 adults with cardiovascular disease and overweight or obesity | Semaglutide vs placebo | Mean 39.8 months | Major cardiovascular events | 6.5% vs 8.0%; HR 0.80. | No setmelanotide equivalent exists. |
Different Receptors, Different Warnings
Because they act on different receptors, the two drugs have largely different safety profiles. Only semaglutide carries a boxed warning.
FDA Boxed Warning (semaglutide only): Risk of Thyroid C-Cell Tumors
Wegovy and other semaglutide labels carry a boxed warning for thyroid C-cell tumors seen in rodents; human relevance is unknown. Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Imcivree has no boxed warning.
Skin and mood monitoring with setmelanotide
The Imcivree label warns of generalized skin darkening, darkening of existing moles and new moles, and advises a full-body skin examination before and during treatment. It also warns of depression and suicidal thoughts, spontaneous erections and other sexual effects, and serious allergic reactions.
| Safety Consideration | Setmelanotide | Semaglutide |
|---|---|---|
| Most common adverse reactions | Skin hyperpigmentation, injection-site reactions, nausea, headache, diarrhoea, abdominal pain, vomiting, depression, spontaneous erection | Nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness |
| Skin and moles | Skin darkening in 61% of the Bardet-Biedl trial; label requires skin examinations | Not listed among Wegovy label warnings |
| Mood | Label warning for depression and suicidal ideation | Wegovy's former suicidal behavior and ideation warning was removed from the label in February 2026 |
| Condition-specific warnings | Adrenal insufficiency and sodium imbalance in hypothalamic obesity | Pancreatitis, gallbladder disease, hypoglycaemia with insulin or secretagogues, kidney injury from dehydration, heart-rate increase, diabetic retinopathy complications in type 2 diabetes |
What Setmelanotide and Semaglutide Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Both reduce appetite-driven weight gain
Each lowers body weight by acting on appetite signalling, through different receptors.
Both are FDA-approved injected peptides
Each has a U.S. label for long-term weight reduction in a defined population.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Different patients
Setmelanotide is for specific rare genetic and hypothalamic obesity; semaglutide is for common obesity. A genetic or clinical diagnosis decides eligibility for setmelanotide.
Different receptors
Setmelanotide activates the MC4 receptor; semaglutide the GLP-1 receptor.
Different size of evidence
Setmelanotide trials enrolled tens of people; semaglutide trials enrolled thousands.
Different safety profiles
Skin darkening, mood and sexual effects for setmelanotide; gastrointestinal effects and a thyroid boxed warning for semaglutide.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Setmelanotide is a stronger weight-loss drug anyone can use instead of semaglutide
Not supportedApproved only for Bardet-Biedl syndrome, genetically confirmed POMC, PCSK1 or LEPR deficiency, and acquired hypothalamic obesity.
Setmelanotide works by replacing a signal missing in specific rare disorders. Its label states it would not be expected to work in general obesity, and it has not been tested there in the approved trials.
Semaglutide is the right treatment for rare genetic obesity
UnprovenWegovy's label covers common obesity; treatment of rare disorders is a specialist decision.
There are no randomized semaglutide trials in these rare disorders; the published evidence is limited to case reports, such as two pediatric patients with Bardet-Biedl or Alström syndrome.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Weight loss in common obesity
Semaglutide has large randomized trials; setmelanotide is not indicated or established here.
Weight loss in approved rare obesity disorders
Setmelanotide has small but consistent rare-disease trials, including one randomized trial; semaglutide has case reports only.
Cardiovascular outcomes
SELECT showed fewer events with semaglutide; no outcomes data exist for setmelanotide.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
GLP-1 drugs in rare obesity
Whether semaglutide helps people with Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency has not been tested in randomized trials.
Long-term setmelanotide data
Rare-disease trials are small and short relative to lifelong treatment; long-term outcomes and safety in children need more follow-up.
Combination use
No published trial has tested setmelanotide and a GLP-1 drug together.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Single-arm Phase 3 trials
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials10 participants with POMC deficiency and 11 with LEPR deficiency.
-
Randomized controlled trial · Rare disease
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period38 patients; 14-week placebo period then 52 weeks open-label.
-
Randomized controlled trial · Rare disease
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity120 participants aged 4 to 66; 52 weeks.
-
Case series
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor AgonistFirst two patients treated.
-
Official U.S. prescribing information
Imcivree (setmelanotide) injection, current U.S. labelIncludes the limitation that Imcivree is not indicated for general (polygenic) obesity. Checked 11 October 2026.
-
FDA approval record
Drugs@FDA: Imcivree, NDA 213793
-
Randomized controlled trial · Obesity
Once-Weekly Semaglutide in Adults with Overweight or ObesityDouble-blind, 68 weeks, 1,961 adults without diabetes; funded by Novo Nordisk.
-
Cardiovascular outcomes trial
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes17,604 adults with cardiovascular disease and overweight or obesity; funded by Novo Nordisk.
-
Official U.S. prescribing information
Wegovy injection and tablets, current U.S. labelChecked 11 October 2026.
-
Official U.S. prescribing information
Ozempic injection, current U.S. labelChecked 11 October 2026.
-
Case report
Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström SyndromeTwo pediatric cases; no control group.